Key result
Replacing trivalent oral poliovirus vaccines with bivalent types aims to prevent circulating vaccine-derived poliovirus transmission.
Answers are grounded in this paper and cite their sources.
In April and May, 2016, the Global Polio Eradication Initiative (GPEI) withdrew the live attenuated Sabin type 2 poliovirus from trivalent oral poliovirus vaccine (tOPV) and replaced it with bivalent types 1 and 3 oral poliovirus vaccine (bOPV).1 This switch was facilitated by certification of wild poliovirus type 2 eradication in September, 2015.2 The switch, as part of sequential withdrawal of Sabin strains,3 was necessary because continued use of oral poliovirus vaccine would invariably be followed by endemic and epidemic transmission of circulating vaccine-derived polioviruses with neurovirulence and transmissibility properties of wild polioviruses and, thus, not compatible with eradication.
No takes yet. Share an insight, caveat, or question.
Garon et al. (2017) studied Poliovirus. Switch from trivalent oral poliovirus vaccine (tOPV) to bivalent oral poliovirus vaccine (bOPV) was evaluated. The Global Polio Eradication Initiative replaced trivalent oral poliovirus vaccine with bivalent types 1 and 3 to prevent transmission of circulating vaccine-derived polioviruses.
Synapse has enriched 10 related papers. Consider them for comparative context: